LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a medical device for male and female hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; Nava MD, a female-oriented tele-dermatology and skincare brand that would offer virtual medical treatment from dermatologists and other providers; and iNR Wellness MD, a supplement for immune and digestive support. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: lifemd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/23/2024 | $11.00 | Buy | B. Riley Securities |
| 6/5/2024 | $12.00 | Overweight | KeyBanc Capital Markets |
| 11/30/2023 | $10.00 | Buy | Craig Hallum |
| 7/21/2023 | $7.00 | Overweight | Cantor Fitzgerald |
| 7/3/2023 | $9.00 | Buy | H.C. Wainwright |
| 3/10/2022 | $14.00 | Buy | Colliers Securities |
| 10/4/2021 | $16.00 | Buy | B. Riley Securities |
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of November: Craig-Hallum 15th Annual Alpha Select Conference, November 19 at the Sheraton NY Times Square Hotel. Management will hold one-on-one meetings with investors. Stephens NASH24 Conference, November 20 at the Grand Hyatt Nashville. Management will hold one-on-one meetings with investors.BTIG Digital Health Forum, November 25. Management will participate in a virtual panel discussion titled "Primary Care is the Solution" at 10:00 a.m. Eastern time a
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on November 7, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 7thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-717-1738International Dial-In:646-307-1865Conference ID:73461Live & Archived Webcast:Link About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmac
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces the launch by its Rex MD men's health brand of TestoRx, a new direct-to-consumer men's hormone therapy telehealth offering. TestoRx offers an initial consultation with requisite blood tests to pre-screen patients, with treatment options that include both replacement therapy and alternative treatments to enhance endogenous hormone production – alongside ongoing telehealth visits and follow-up care. Rex MD is a leading men's telehealth platform that offers access to virtual medical treatment for a variety of men's health needs including erectile dysfunction,
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 4, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or dire
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on October 15, 2024, to holders of record at the close of business on October 4, 2024. About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and wome
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc.® (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced significant enhancements to its weight management program, underscoring the company's commitment to expanding patient access and improving the quality and comprehensiveness of care available on its virtual care platform. The investments include a new and improved platform and partnership for in-home lab collection, technology enhancements for prior authorization and pharmacy benefits infrastructure, and the launch of personalized prescription treatment options. These advancements further establish LifeMD as a leader in the rapidly growing market for
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of September: H.C. Wainwright 26th Annual Global Investment Conference, September 9-11 at the Lotte New York Palace Hotel. Management will deliver a corporate presentation on Monday, September 9th at 12:00 p.m. Eastern time and will hold one-on-one meetings with investors.TD Cowen 9th Annual FutureHealth Conference, September 10 at One Vanderbilt in New York City. Management will participate in a panel discussion on Tuesday, September 10th at 2:20 p.m. Easter
Revenue increased 41% year-over-year to $50.7 million with telehealth revenue up 67%Telehealth achieved standalone profitability one quarter ahead of guidance, with adjusted EBITDA of $820,000Weight management subscribers exceeded 60,000 as of June 30, 2024Adjusted EBITDA increased 44% to $2.5 millionCash of $35.7 million as of June 30, 2024, and positive net cash flow in three of the last four quarters Conference call begins at 4:30 p.m. Eastern time today NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today reported financial results for the three and six months ended June 30, 2024. Management Commentary "L
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Revenue of $168.6 million, with revenue per active earning Coach of $4,972 Independent active earning OPTAVIA Coaches of 33,900 Net loss of $8.2 million (non-GAAP adjusted net income of $10.1 million) Loss per diluted share of $0.75 (non-GAAP adjusted earnings per share ("EPS") of $0.92) Cash, Cash Equivalents, and Investment Securities of $163.5 million with zero debt "We are acting decisively to transform our business to position us for long-term growth, with
10-Q - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
424B3 - LifeMD, Inc. (0000948320) (Filer)
10-Q - LifeMD, Inc. (0000948320) (Filer)
EFFECT - LifeMD, Inc. (0000948320) (Filer)
EFFECT - LifeMD, Inc. (0000948320) (Filer)
S-3/A - LifeMD, Inc. (0000948320) (Filer)
S-8 - LifeMD, Inc. (0000948320) (Filer)
S-3/A - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
Keybanc analyst Scott Schoenhaus maintains LifeMD (NASDAQ:LFMD) with a Overweight and lowers the price target from $12 to $10.
LifeMD, Inc. (NASDAQ:LFMD) today announced the launch of private health insurance acceptance for its virtual primary care services, including weight management for medically qualified patients. Initially available in select states, the company plans to continue enrollments with private payors to facilitate access to medically necessary services, ultimately having broad coverage options across all 50 states. As part of its early 2025 roadmap, LifeMD expects to begin accepting Medicare.
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
Keybanc analyst Scott Schoenhaus initiates coverage on LifeMD (NASDAQ:LFMD) with a Overweight rating and announces Price Target of $12.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume CERE PUT TRADE NEUTRAL 07/19/24 $40.00 $56.0K 3 2.9K LFMD CALL SWEEP BULLISH 11/15/24 $7.50 $54.4K 2.
- SEC Filing
B. Riley Securities analyst William Woods reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $12 price target.
B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $11.00
KeyBanc Capital Markets initiated coverage of LifeMD with a rating of Overweight and set a new price target of $12.00
Craig Hallum initiated coverage of LifeMD with a rating of Buy and set a new price target of $10.00
Cantor Fitzgerald initiated coverage of LifeMD with a rating of Overweight and set a new price target of $7.00
H.C. Wainwright initiated coverage of LifeMD with a rating of Buy and set a new price target of $9.00
Colliers Securities initiated coverage of LifeMD with a rating of Buy and set a new price target of $14.00
B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $16.00
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on November 7, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 7thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-717-1738International Dial-In:646-307-1865Conference ID:73461Live & Archived Webcast:Link About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmac
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 4, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or dire
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on October 15, 2024, to holders of record at the close of business on October 4, 2024. About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and wome
Revenue increased 41% year-over-year to $50.7 million with telehealth revenue up 67%Telehealth achieved standalone profitability one quarter ahead of guidance, with adjusted EBITDA of $820,000Weight management subscribers exceeded 60,000 as of June 30, 2024Adjusted EBITDA increased 44% to $2.5 millionCash of $35.7 million as of June 30, 2024, and positive net cash flow in three of the last four quarters Conference call begins at 4:30 p.m. Eastern time today NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today reported financial results for the three and six months ended June 30, 2024. Management Commentary "L
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Revenue of $168.6 million, with revenue per active earning Coach of $4,972 Independent active earning OPTAVIA Coaches of 33,900 Net loss of $8.2 million (non-GAAP adjusted net income of $10.1 million) Loss per diluted share of $0.75 (non-GAAP adjusted earnings per share ("EPS") of $0.92) Cash, Cash Equivalents, and Investment Securities of $163.5 million with zero debt "We are acting decisively to transform our business to position us for long-term growth, with
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on August 7, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Wednesday, August 7thTime:4:30 p.m. Eastern timeToll-Free Dial-In:1-800-245-3047International Dial-In:1-203-518-9765Conference ID:LIFEMDLive & Archived Webcast:Link About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, an
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the second quarter ended June 30, 2024 on Monday, August 5, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 5, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2024, to holders of record at the close of business on July 5, 2024. About LifeMD, Inc. LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's healt
First quarter revenue increased 33% year-over-year to $44.1 million with telehealth revenue growing 53% versus the year-ago period.Raising full-year revenue guidance to at least $205 million, up from prior guidance of at least $200 million.Growth in all business segments, with weight management subscribers growing to 42,000 as of March 31, 2024. As of today, weight management subscribers exceed 50,000.Including the increase in deferred revenue from prepaid weight management subscriptions, cash-adjusted EBITDA was $4.8 million, a 108% increase versus the comparable measure in the year-ago period. Excluding this increase, adjusted EBITDA for the first quarter was $0.5 million.Generated $5.2 mi
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)
SC 13D - LifeMD, Inc. (0000948320) (Subject)
SC 13D/A - LifeMD, Inc. (0000948320) (Subject)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
3 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec
NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors. With Dr. LaRovere's appointment, LifeMD's Board will comprise nine directors, seven of whom are independent. "We are pleased to welcome Dr. LaRovere to the LifeMD Board," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Dr. LaRovere's leadership and clinical experience at two of the top hospitals in the world, combined with her deep background in healthcare data, analytics, machine learning, and artificial intelligence will be invaluable to LifeMD as we grow our bus
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Jessica Friedeman as Chief Marketing Officer. Friedeman succeeds Stefan Galluppi, who continues as LifeMD's Chief Innovation Officer. Friedeman brings nearly twenty years' experience engaging and retaining patients, with a proven track record of increasing efficiency and revenue by executing go-to-market product strategy for forward-thinking, high growth companies. She offers specialized knowledge in customer relationship management, SaaS technology, and the application of actionable insights through data science. Friedeman has
NEW YORK, Sept. 20, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, is pleased to announce its appointment of Bobby Jindal, the 55th Governor of the State of Louisiana, to its board of directors. Mr. Jindal was elected as the nation's youngest governor in 2007 and spent two terms as Louisiana's chief executive officer to rebuild and diversify the state's economy and financial footing in the aftermath of Hurricanes Katrina and Rita. Prior to serving as Governor, Mr. Jindal held positions as the head of the Louisiana Department of Health and Hospitals, President of the University of Louisiana System, Assistant Secretary of the U.S. Depart
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced its appointment of Naveen Bhatia to its board of directors. Mr. Bhatia is a private investor and has served as a director of numerous public and private companies; currently, he serves on the Board of Directors of Blue Yonder, EquipmentShare, RG Barry, and CRG Financial. He also previously served as the Chairman of the Board of Cotton Holdings from 2010-2019. From 2013 to 2020, Mr. Bhatia was a Senior Director in the Tactical Opportunities group of Blackstone, involved with sourcing, evaluating, and executing investment opportunities. "We are ex
NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. ("the Company") (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced the appointment of prominent dermatologist and surgeon, Dr. Matthew Zipoli, as a medical advisor for tele-dermatology brand Nava MD. Dr. Zipoli will collaborate with the Company to further enhance the brand's development goals. With over two decades of experience, Dr. Zipoli is a leading specialist in Mohs Surgery for the treatment of skin cancers. He is affiliated with Mount Auburn and Emerson Hospitals in the greater-Boston area, and serves as a Clinical Instructor at Tufts University School of Medicine. Dr. Zipoli graduated from Boston U
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the fourth quarter and full year ended December 31, 2020. All quarterly and full year comparisons are to the same year-ago period. The company will hold a conference call at 4:30 p.m. Eastern time today to discuss the results (see dial-in information below.) Q4 Financial Highlights Revenue increased 227% to a record $12.9 million.82% of Q4 2020 revenue was generated by subscriptions, up from 48% in Q4 2019.Telemedicine net orders increased 275% to more than 117,000.Annual recurring revenue (ARR) from subscriptions at December 31, 2020 reached $53